Patent ID: 8124603
Filing Date: 2012-02-28
Classification: A61K,A61P

Abstract:
1. A crystalline form of meloxicam, which has improved bioavailability, an enhanced rate of dissolution and shorter time to C max in blood when compared to the bioavailability, rate of dissolution, and time to C max , of marketed pure meloxicam, selected from the group consisting of co-crystal meloxicam:fumaric acid, co-crystal meloxicam:succinic acid, co-crystal meloxicam:adipic acid; co-crystal meloxicam:benzoic acid, co-crystal meloxicam:DL-malic acid, co-crystal meloxicam:L-malic acid, co-crystal meloxicam:glutaric acid, co-crystal meloxicam:acetylsalicylic acid, co-crystal meloxicam:salicylic acid form I, co-crystal meloxicam:salicylic acid form II, co-crystal meloxicam:salicylic acid form III, co-crystal meloxicam:1-hydroxy-2-naphthoic acid, co-crystal meloxicam:maleic acid, co-crystal meloxicam:4-hydroxybenzoic acid, co-crystal meloxicam:malonic acid, co-crystal meloxicam:glycolic acid, co-crystal meloxicam:2,5-dihydroxybenzoic acid form I, co-crystal meloxicam:2,5-dihydroxybenzoic acid form II, co-crystal meloxicam:camphoric acid form I, co-crystal meloxicam:camphoric acid form II, co-crystal meloxicam:maltol, co-crystal meloxicam :ethyl maltol, and co-crystal meloxicam:hydrocinnamic acid.